U.S. Stocks Rise, Nasdaq Gains Over 200 Points
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Source: Benzinga
- Nasdaq Performance: The Nasdaq Composite rose over 200 points on Friday, closing at 22,917.24, indicating strong demand for tech stocks and potentially reflecting investor optimism about future economic recovery.
- PPL Corporation Earnings: PPL Corporation reported mixed Q4 fiscal 2025 results with operating revenue of $2.27 billion, falling short of the $2.42 billion consensus estimate, although adjusted EPS of 41 cents met analyst expectations, highlighting challenges in revenue growth.
- Dividend Increase: PPL raised its quarterly dividend by 4.6% to 28.50 cents per share, demonstrating confidence in future cash flows and a commitment to shareholder returns amidst fluctuating earnings.
- Market Dynamics: On Friday, communication services stocks gained 2.3%, while healthcare stocks fell by 0.7%, indicating performance disparities across sectors that may influence investors' asset allocation strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 66.570
Low
38.00
Averages
60.86
High
83.71
Current: 66.570
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL Secures $110 Million Financing from Samsung Affiliates
- Successful Financing: GRAIL has closed a $110 million equity financing with Samsung affiliates, purchasing shares at $70.05 each, which significantly strengthens the company's financial position and cash runway to support its international expansion objectives.
- Deepening Strategic Collaboration: This financing will enhance GRAIL's collaboration with Samsung C&T to commercialize the Galleri multi-cancer early detection test in South Korea, with potential expansion into Japan and Singapore, indicating GRAIL's growth potential in the Asian market.
- Driving Technological Innovation: The Galleri test screens for over 50 cancer types and has been clinically proven to increase early cancer detection rates while reducing Stage IV diagnoses, which is expected to significantly improve treatment options and outcomes for patients.
- Broad Market Prospects: GRAIL aims to transform the landscape of early cancer detection through innovative screening technologies, and this financing and collaboration will accelerate its market penetration in the Asia-Pacific region to meet the growing demand for cancer screening.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter is accused of inflating financial results by pulling forward customer orders during the class period from April 2024 to April 2026, which has severely undermined investor confidence in the company's future performance, likely impacting its stock price.
- PicS N.V. Lawsuit: PicS is alleged to have failed to disclose deficiencies in its credit evaluation procedures during its 2026 IPO, leading to a reclassification of approximately R$590 million in exposures and an incremental ECL charge of R$88 million, potentially causing long-term damage to its market reputation.
- Verra Mobility Lawsuit: Verra Mobility is accused of not disclosing its reliance on contract renewal with Avis for its 2026 growth plan, which may result in its full-year guidance being unmet, thereby affecting investor confidence and stock performance.
- Grail, Inc. Lawsuit: Grail is alleged to have been overly optimistic about its clinical trial results from 2025 to 2026, ignoring potential negative trends, which could lead to a decline in investor trust regarding its future prospects, adversely affecting its market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled investors regarding the NHS-Galleri trial's prospects for reducing Stage III-IV cancers, concealing adverse facts while presenting an overly optimistic view, leading to significant investor losses once the truth emerged.
- Market Reaction: Following the revelation of GRAIL's misleading statements, investor losses increased significantly, indicating that the company's public disclosures throughout the class period were false and materially misleading, adversely affecting investor decisions.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
Investigation into Grail, Inc. Shareholder Claims
- False Statement Investigation: Moore Law, PLLC is investigating whether Grail, Inc.'s officers and directors made false and misleading statements that could lead to economic losses for shareholders, highlighting potential governance risks within the company.
- Stock Price Plunge: Grail's stock price fell from $101.53 per share on February 19, 2026, to $50.21 per share the following day, representing a decline of approximately 50.55%, indicating severe market concerns about the company's true condition.
- Investor Losses: Due to the alleged false statements by executives, investors who purchased shares during this period face significant economic losses, which may lead to a decline in trust regarding the company's future performance and market standing.
- Legal Implications: Affected shareholders may pursue litigation through Moore Law to seek monetary damages and corporate governance reforms, suggesting that legal actions could have profound implications for the company's future operations.
See More
Grail Class Action Lawsuit Initiated Against Executives
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc., representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statements Allegations: The lawsuit claims that Grail misrepresented its confidence in achieving significant reductions in late-stage cancers in the NHS-Galleri trial, failing to disclose adverse facts that could impact the trial's outcomes, resulting in substantial investor losses.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the primary endpoint of statistically significant reduction in late-stage cancers was not observed, Grail's stock price fell by over 50%, indicating a severe market reaction to the company's prospects.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in pursuit of compensation, highlighting legal protections for investor rights.
See More
GRAIL Faces Class Action After Trial Failure
- Market Capitalization Loss: GRAIL, Inc. lost over $2.2 billion in market capitalization following the NHS-Galleri trial readout, leading to significant investor losses and reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Lawsuit: Investors have initiated a class action lawsuit against GRAIL and its executives for alleged violations of federal securities laws, seeking compensation for losses incurred from May 13, 2025, to February 19, 2026, indicating strong dissatisfaction with the company's disclosures.
- Trial Design Controversy: The lawsuit centers on GRAIL's disclosures about the NHS-Galleri trial design, alleging that the company misled investors by claiming that a three-year follow-up period was sufficient to meet the primary endpoint, while concealing critical information that suggested a longer duration was necessary, impacting investor decisions.
- Severe Market Reaction: Following the announcement on February 19, 2026, that the trial failed to achieve its primary endpoint, GRAIL's stock price plummeted over 50% the next day, indicating a sharp decline in investor confidence in the management, further exacerbating legal risks.
See More
GRAIL Secures $110 Million Financing from Samsung Affiliates
- Successful Financing: GRAIL has closed a $110 million equity financing with Samsung affiliates, purchasing shares at $70.05 each, which significantly strengthens the company's financial position and cash runway to support its international expansion objectives.
- Deepening Strategic Collaboration: This financing will enhance GRAIL's collaboration with Samsung C&T to commercialize the Galleri multi-cancer early detection test in South Korea, with potential expansion into Japan and Singapore, indicating GRAIL's growth potential in the Asian market.
- Driving Technological Innovation: The Galleri test screens for over 50 cancer types and has been clinically proven to increase early cancer detection rates while reducing Stage IV diagnoses, which is expected to significantly improve treatment options and outcomes for patients.
- Broad Market Prospects: GRAIL aims to transform the landscape of early cancer detection through innovative screening technologies, and this financing and collaboration will accelerate its market penetration in the Asia-Pacific region to meet the growing demand for cancer screening.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter is accused of inflating financial results by pulling forward customer orders during the class period from April 2024 to April 2026, which has severely undermined investor confidence in the company's future performance, likely impacting its stock price.
- PicS N.V. Lawsuit: PicS is alleged to have failed to disclose deficiencies in its credit evaluation procedures during its 2026 IPO, leading to a reclassification of approximately R$590 million in exposures and an incremental ECL charge of R$88 million, potentially causing long-term damage to its market reputation.
- Verra Mobility Lawsuit: Verra Mobility is accused of not disclosing its reliance on contract renewal with Avis for its 2026 growth plan, which may result in its full-year guidance being unmet, thereby affecting investor confidence and stock performance.
- Grail, Inc. Lawsuit: Grail is alleged to have been overly optimistic about its clinical trial results from 2025 to 2026, ignoring potential negative trends, which could lead to a decline in investor trust regarding its future prospects, adversely affecting its market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled investors regarding the NHS-Galleri trial's prospects for reducing Stage III-IV cancers, concealing adverse facts while presenting an overly optimistic view, leading to significant investor losses once the truth emerged.
- Market Reaction: Following the revelation of GRAIL's misleading statements, investor losses increased significantly, indicating that the company's public disclosures throughout the class period were false and materially misleading, adversely affecting investor decisions.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
Investigation into Grail, Inc. Shareholder Claims
- False Statement Investigation: Moore Law, PLLC is investigating whether Grail, Inc.'s officers and directors made false and misleading statements that could lead to economic losses for shareholders, highlighting potential governance risks within the company.
- Stock Price Plunge: Grail's stock price fell from $101.53 per share on February 19, 2026, to $50.21 per share the following day, representing a decline of approximately 50.55%, indicating severe market concerns about the company's true condition.
- Investor Losses: Due to the alleged false statements by executives, investors who purchased shares during this period face significant economic losses, which may lead to a decline in trust regarding the company's future performance and market standing.
- Legal Implications: Affected shareholders may pursue litigation through Moore Law to seek monetary damages and corporate governance reforms, suggesting that legal actions could have profound implications for the company's future operations.
See More
Grail Class Action Lawsuit Initiated Against Executives
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc., representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statements Allegations: The lawsuit claims that Grail misrepresented its confidence in achieving significant reductions in late-stage cancers in the NHS-Galleri trial, failing to disclose adverse facts that could impact the trial's outcomes, resulting in substantial investor losses.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the primary endpoint of statistically significant reduction in late-stage cancers was not observed, Grail's stock price fell by over 50%, indicating a severe market reaction to the company's prospects.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in pursuit of compensation, highlighting legal protections for investor rights.
See More
GRAIL Faces Class Action After Trial Failure
- Market Capitalization Loss: GRAIL, Inc. lost over $2.2 billion in market capitalization following the NHS-Galleri trial readout, leading to significant investor losses and reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Lawsuit: Investors have initiated a class action lawsuit against GRAIL and its executives for alleged violations of federal securities laws, seeking compensation for losses incurred from May 13, 2025, to February 19, 2026, indicating strong dissatisfaction with the company's disclosures.
- Trial Design Controversy: The lawsuit centers on GRAIL's disclosures about the NHS-Galleri trial design, alleging that the company misled investors by claiming that a three-year follow-up period was sufficient to meet the primary endpoint, while concealing critical information that suggested a longer duration was necessary, impacting investor decisions.
- Severe Market Reaction: Following the announcement on February 19, 2026, that the trial failed to achieve its primary endpoint, GRAIL's stock price plummeted over 50% the next day, indicating a sharp decline in investor confidence in the management, further exacerbating legal risks.
See More
